InvestSMART

Alcidion Group Limited (ASX:ALC)

ALERT: Price-sensitive ASX Announcement for ALC
Current share price for ALC : $0.091 -0.007 (-7.14%)+
Announcement
Release
28 Oct 2025 8:23AM
Price at Release
$0.098
Full Release
download
Summary
Alcidion Group Limited reported a strong performance in its Q1 FY26 Quarterly Activities Report, with new total contract value (TCV) sales amounting to $8.2 million, including a significant $6.8 million expansion of the North Cumbria contract. The company achieved a dramatic reduction in operating cash outflows, reporting $0.6 million versus $3.9 million in the previous corresponding period. As of 30 September 2025, Alcidion had $36.3 million in contracted revenue for FY26 and a cash balance of $16.4 million with no debt. CEO Kate Quirke highlighted the successful deployment of their solutions in major hospitals such as University Hospitals Southampton NHS Foundation Trust and North Adelaide Local Health Network. Alcidion remains confident in delivering a positive EBITDA and operating cash flow for FY26, with the potential for increased sales throughout the year. The company's financial stability and growth are further supported by its strong cash receipts and strategic contract expansions.
Key Points
  • Q1 TCV sales of $8.2M with a $6.8M North Cumbria contract expansion.
  • Operating cash outflow of $0.6M, improved from $3.9M in Q1 FY25.
  • Cash receipts of $8.4M, up from $6.3M in prior corresponding period.
  • $36.3M in FY26 contracted revenue as of 30 September 2025.
  • Cash balance of $16.4M and no debt as of 30 September 2025.
  • Successful deployments at University Hospitals Southampton NHS Foundation Trust and North Adelaide Local Health Network.
  • Reaffirmation of positive EBITDA and operating cash flow guidance for FY26.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.